Key result
Direct oral anticoagulation did not reduce the risk of recurrent stroke compared with aspirin in patients with embolic stroke of undetermined source, but increased bleeding.
Why the study?
The study evaluated the efficacy and safety of direct oral anticoagulation compared with antiplatelet therapy for secondary stroke prevention in adult patients with embolic stroke of undetermined source.
Does direct oral anticoagulation reduce recurrent stroke in adult patients with embolic stroke of undetermined source compared with antiplatelet therapy?
Meta-Analysis (n=12,603)
Does direct oral anticoagulation reduce recurrent stroke in adult patients with embolic stroke of undetermined source compared with antiplatelet therapy?
Answers are grounded in this paper and cite their sources.
Routine use of direct oral anticoagulants instead of aspirin in patients with embolic stroke of undetermined source does not reduce recurrent stroke and increases bleeding risk.
Purpose We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of direct oral anticoagulation (DOAC) compared with antiplatelet therapy for secondary stroke prevention in adult patients with embolic stroke of undetermined source (ESUS). Method We searched major databases (Embase, MEDLINE, CINAHL, CENTRAL, and Web of Science) for RCTs published until March 2021. The primary outcome was recurrent stroke, and the main safety outcomes were major bleeding and clinically relevant non-major bleeding (CRNB). We assessed risk of bias using the Cochrane Risk of Bias tool. We used a random-effects model to determine pooled risk ratios and 95% confidence intervals in the datasets and key subgroups. Findings Our search identified two RCTs, involving a total of 12,603 patients with ESUS. Anticoagulation with dabigatran or rivaroxaban compared with aspirin did not reduce the risk of recurrent stroke (RR, 0.96 [0.76–1.20]) or increase major bleeding (RR, 1.77 [0.80–3.89]) but significantly increased the composite of major or clinically relevant non-major bleeding (RR, 1.57 [1.26–1.97]). Prespecified subgroup analysis demonstrated consistent results according to age and sex. Additional post-hoc subgroup analyses demonstrated consistent results according to prior stroke and presence of a patent foramen ovale but suggested that DOACs reduced recurrent stroke in patients with an estimated glomerular filtration rate (eGFR) <50 and 50-80 ml/min but not in those with eGFR >80 ml/min (interaction P = 0.0234). Discussion/conclusion Direct oral anticoagulations are not more effective than aspirin in preventing stroke recurrence in patients with ESUS and increase bleeding.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2022) conducted a meta-analysis in Embolic stroke of undetermined source (ESUS) (n=12,603). Direct oral anticoagulation (dabigatran or rivaroxaban) vs. Antiplatelet therapy (aspirin) was evaluated on Recurrent stroke (RR 0.96, 95% CI 0.76-1.20, p=0.71). Direct oral anticoagulation did not reduce the risk of recurrent stroke compared with aspirin in patients with embolic stroke of undetermined source, but increased bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: